Physician profile
Olivia Ann Simpson
NPI 1497214654
$3,714.40
in general payments reported to CMS, 2019-2025
21 companies · $643 in 2025
The $643 reported for 2025 was more than what 99% of Reproductive Endocrinology/Infertility providers received nationally (typical 2025 total: $63.48).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.25 · 2023: $131 · 2024: $2,919 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220 · Travel and Lodging: $1,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.81 |
| Travel and Lodging | $1,473.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,457.94 | 2024-2025 | Linq II, Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $409.29 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.02 | 2025 | |
| Merck Sharp & Dohme LLC | $102.40 | 2023-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $76.00 | 2024-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.39 | 2024 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $65.98 | 2024 | Arcalyst |
| Vital Connect, INC | $60.54 | 2025 | Vitalpatch Rtm |
| Novo Nordisk INC | $58.95 | 2025 | Wegovy |
| Scpharmaceuticals INC. | $57.04 | 2024-2025 | |
| Bridgebio Pharma, INC. | $41.89 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $27.02 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals, Ltd. | $25.39 | 2023 | Arcalyst |
| Philips North America LLC | $21.66 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Abbvie INC. | $21.25 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21.14 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.86 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $18.91 | 2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $16.82 | 2024 | Amvuttra |
| Abbott Laboratories | $16.38 | 2024 | Allure Quadra |
| Amgen INC. | $13.53 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.